HRP20160110T1 - Priprema nalmefen hidroklorida iz naltreksona - Google Patents

Priprema nalmefen hidroklorida iz naltreksona Download PDF

Info

Publication number
HRP20160110T1
HRP20160110T1 HRP20160110TT HRP20160110T HRP20160110T1 HR P20160110 T1 HRP20160110 T1 HR P20160110T1 HR P20160110T T HRP20160110T T HR P20160110TT HR P20160110 T HRP20160110 T HR P20160110T HR P20160110 T1 HRP20160110 T1 HR P20160110T1
Authority
HR
Croatia
Prior art keywords
process according
mthf
naltrexone
methyltriphenylphosphonium
nalmefene
Prior art date
Application number
HRP20160110TT
Other languages
English (en)
Croatian (hr)
Inventor
Carla De Faveri
Mauro Casarin
Michele Brusegan
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43222172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20160110(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HRP20160110T1 publication Critical patent/HRP20160110T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08Oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
HRP20160110TT 2009-05-25 2010-05-21 Priprema nalmefen hidroklorida iz naltreksona HRP20160110T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200900650 2009-05-25
US18102209P 2009-05-26 2009-05-26
PCT/DK2010/050110 WO2010136039A1 (en) 2009-05-25 2010-05-21 Preparation of nalmefene hydrochloride from naltrexone
EP10720257.4A EP2435439B8 (en) 2009-05-25 2010-05-21 Preparation of nalmefene hydrochloride from naltrexone

Publications (1)

Publication Number Publication Date
HRP20160110T1 true HRP20160110T1 (hr) 2016-03-11

Family

ID=43222172

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160110TT HRP20160110T1 (hr) 2009-05-25 2010-05-21 Priprema nalmefen hidroklorida iz naltreksona

Country Status (35)

Country Link
US (1) US8598352B2 (enExample)
EP (1) EP2435439B8 (enExample)
JP (1) JP5794980B2 (enExample)
KR (1) KR101716522B1 (enExample)
CN (1) CN102459276B (enExample)
AR (1) AR076891A1 (enExample)
AU (1) AU2010252392B2 (enExample)
BR (1) BRPI1010975B1 (enExample)
CA (1) CA2763093C (enExample)
CL (1) CL2011002974A1 (enExample)
CO (1) CO6470832A2 (enExample)
CR (1) CR20110612A (enExample)
DK (1) DK2435439T3 (enExample)
DO (1) DOP2011000362A (enExample)
EA (1) EA019331B1 (enExample)
ES (1) ES2564006T3 (enExample)
GE (1) GEP20146190B (enExample)
HR (1) HRP20160110T1 (enExample)
HU (1) HUE026892T2 (enExample)
IL (1) IL216422A (enExample)
MA (1) MA33368B1 (enExample)
ME (1) ME02622B (enExample)
MX (1) MX2011012502A (enExample)
MY (1) MY158251A (enExample)
NZ (1) NZ596988A (enExample)
PL (1) PL2435439T3 (enExample)
RS (1) RS54599B1 (enExample)
SG (1) SG176205A1 (enExample)
SI (1) SI2435439T1 (enExample)
SM (1) SMT201600061B (enExample)
TN (1) TN2011000590A1 (enExample)
TW (1) TWI469985B (enExample)
UA (1) UA106752C2 (enExample)
WO (1) WO2010136039A1 (enExample)
ZA (1) ZA201108659B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI478928B (zh) 2010-06-11 2015-04-01 Rhodes Technologies 用於製備n-烯丙基化合物之過渡金屬催化的製程及其用途
HRP20170379T1 (hr) 2010-11-05 2017-05-05 H. Lundbeck A/S Postupak proizvodnje naltreksona
CN103012416B (zh) * 2011-09-28 2015-07-01 辽宁海思科制药有限公司 一种盐酸纳美芬的制备方法
TWI560170B (en) 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
CN102584840A (zh) * 2011-12-28 2012-07-18 南京优科生物医药有限公司 一种制备纳美芬化合物的方法
WO2013164383A1 (en) 2012-05-03 2013-11-07 H. Lundbeck A/S Method for the manufacturing of naltrexone
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
CN103204859B (zh) * 2013-04-25 2015-12-02 四川海思科制药有限公司 一种盐酸纳美芬化合物及其制备方法
AR096851A1 (es) 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
AU2014368548B2 (en) 2013-12-20 2019-09-19 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
MX2016013889A (es) 2014-04-22 2017-03-09 Otsuka Pharma Co Ltd Medicamento.
CN104513251A (zh) * 2014-11-28 2015-04-15 安徽悦康凯悦制药有限公司 一种盐酸纳美芬的制备方法
US9757372B2 (en) * 2015-03-25 2017-09-12 Taiwanj Pharmaceuticals Co., Ltd. Toll-like receptor 4 antagonists and use in autoimmune liver diseases
RU2712232C1 (ru) * 2018-10-05 2020-01-27 Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства Улучшенный способ получения налмефена из налтрексона
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
MX2023005055A (es) 2020-11-02 2023-07-14 Rhodes Tech Proceso de purificacion de noroximorfona.
WO2022165040A1 (en) 2021-01-28 2022-08-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN117843650A (zh) * 2023-12-27 2024-04-09 南京海纳医药科技股份有限公司 一种盐酸纳美芬的精制方法
CN117986261B (zh) * 2024-04-02 2024-06-18 成都瑞尔医药科技有限公司 一种盐酸纳美芬母液的回收套用方法
CN119080788A (zh) * 2024-08-19 2024-12-06 南京海鲸药业股份有限公司 一种盐酸纳美芬杂质的去除监控系统及去除方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341764A (en) 1980-03-05 1982-07-27 Cutter Laboratories, Inc. Method of preparing fibronectin and antihemophilic factor
US4322426A (en) 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4535157A (en) * 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
US7687646B2 (en) 2006-03-28 2010-03-30 Azad Pharmaceutical Ingredients, Ag Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene

Also Published As

Publication number Publication date
TWI469985B (zh) 2015-01-21
EA019331B1 (ru) 2014-02-28
MY158251A (en) 2016-09-30
CL2011002974A1 (es) 2012-04-13
CN102459276A (zh) 2012-05-16
MX2011012502A (es) 2011-12-12
NZ596988A (en) 2013-03-28
CA2763093C (en) 2017-03-07
SMT201600061B (it) 2016-07-01
JP2012527489A (ja) 2012-11-08
WO2010136039A1 (en) 2010-12-02
CO6470832A2 (es) 2012-06-29
EA201171461A1 (ru) 2012-05-30
TN2011000590A1 (en) 2013-05-24
PL2435439T3 (pl) 2016-05-31
HUE026892T2 (en) 2016-07-28
UA106752C2 (uk) 2014-10-10
ME02622B (me) 2017-06-20
US8598352B2 (en) 2013-12-03
SI2435439T1 (sl) 2016-06-30
IL216422A (en) 2015-06-30
IL216422A0 (en) 2012-02-29
AU2010252392B2 (en) 2014-10-23
GEP20146190B (en) 2014-11-10
TW201043634A (en) 2010-12-16
CN102459276B (zh) 2016-09-21
MA33368B1 (fr) 2012-06-01
US20120123123A1 (en) 2012-05-17
AU2010252392A1 (en) 2012-01-12
SG176205A1 (en) 2011-12-29
CR20110612A (es) 2012-02-22
KR101716522B1 (ko) 2017-03-14
RS54599B1 (sr) 2016-08-31
AR076891A1 (es) 2011-07-13
ZA201108659B (en) 2013-02-27
CA2763093A1 (en) 2010-12-02
BRPI1010975A2 (pt) 2015-10-20
DOP2011000362A (es) 2012-07-15
EP2435439A1 (en) 2012-04-04
ES2564006T3 (es) 2016-03-17
KR20120023704A (ko) 2012-03-13
JP5794980B2 (ja) 2015-10-14
BRPI1010975B1 (pt) 2021-08-24
EP2435439B1 (en) 2016-01-06
DK2435439T3 (en) 2016-02-29
EP2435439B8 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
HRP20160110T1 (hr) Priprema nalmefen hidroklorida iz naltreksona
ME02316B (me) Imidazopiridazini kao inhibitori akt kinaze
JP2012527489A5 (enExample)
UA114497C2 (uk) Спосіб одержання карбонової кислоти
NZ593529A (en) Improved process for the preparation of oxidized phospholipids
NO20090811L (no) Fremgangsmate for fremstilling av 3(R)-(2-hydroksy-2,2-ditien-2-ylacetoksy)-1-(3-fenoksypropyl)-1-azoniabicyklo[2.2.2]oktanbromid
MX2010008627A (es) Proceso para preparar 2-alcoximetilen-4, 4-difluoro-3-oxobutiratos de alquilo.
PH12013500029A1 (en) Method for synthesizing rare earth metal extractant
CN107382803B (zh) 一种β-羟基苯基硒醚化合物的制备方法
CN102382119B (zh) 一种汉防已甲素和汉防已乙素的提取方法
MY161613A (en) Method for synthesizing rare earth metal extractant
SI2763948T1 (en) Procedure for the isolation of an ingenol
SI2635592T1 (en) Method for obtaining phytosterols and/or tocopherols from residue of a distillation of the esters of vegetable oils, preferably from distillation residue from a transesterification of vegetable oils
TW200613294A (en) Process for preparation of mycophenolic acid and ester derivatives thereof
WO2011083076A8 (en) Improved recovery of nucleic acids from magnetic glass particles
CN1215769C (zh) 乙酰甲胺磷可溶粉的制备方法
CN101941988B (zh) 磷酸二乙酯钠制备磷酸三乙酯的工艺
Donohoe et al. Exerting control over the acyloin reaction
CN117924039A (zh) 苯酚异构体的分离
CN102702280B (zh) 1,6-酐-2-叠氮-2-去氧-4-O-对甲氧苄基-β-D-吡喃葡萄糖苷的提纯方法
CN109517019B (zh) 一种3β-乙酰氧基雄甾-5-烯-17-酮加成反应副产物的再利用方法
CN106187758A (zh) 一种四溴苯甲酸异辛酯的合成方法
Liu et al. Synthesis of cyclocitrinol skeleton via a carbocation rearrangement
CN103724375B (zh) 具有羟基结构的环三磷腈化合物产物后处理方法
WO2011084943A3 (en) Tetrabromophthalic diester flame retardants and their production